Trial results
$SNDX — axatilimab
Syndax Pharmaceuticals Inc (SNDX) axatilimab: trial results in newly diagnosed chronic graft-versus-host disease (GVHD), 2027.
The catalyst
"The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027."
— Syndax Pharmaceuticals, 8-K filed 2026-11-02 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
SNDX-AXATILIMAB-2026- Company
- Syndax Pharmaceuticals Inc
- Kind
- Trial results
- Indication
- newly diagnosed chronic graft-versus-host disease (GVHD)
- Window
- 2027-01-01 – 2027-12-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.